Literature DB >> 17451915

[Painful ophthalmoplegia in children: Tolosa-Hunt syndrome or ophthalmoplegic migraine?].

C Orssaud1, O Roche, H El Dirani, J Allali, J-L Dufier.   

Abstract

In children with painful ophthalmoplegia, the diagnosis of Tolosa-Hunt syndrome or of ophthalmoplegic migraine should only be considered when tumoral, infectious, inflammatory or vascular causes have been excluded by appropriate investigations. Both entities are classified as "neuralgia" by the International Headache Society, and seem to share a similar pathogenic mechanism. Both diseases have many clinical similarities with slight differences concerning pain characteristics or ocular associated symptoms. High resolution CT scan or contrast enhanced MRI can be necessary to exclude other causes of painful ophthalmoplegia. They can sometimes objectify an inflammatory process of the cavernous sinus in Tolosa-Hunt syndrome or a reversible enhancement and thickening of the cisternal segment of the oculomotor nerve during an ophthalmoplegic migraine. Pain and ophthalmoplegia quickly resolve with corticosteroids. Such treatment may decrease the risk of recurrence. It is important to follow-up these patients for a 2 years period and to repeat the etiologic assessment. We report here 2 cases of children with painful ophtalmoplegia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451915     DOI: 10.1016/j.arcped.2007.03.018

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  2 in total

Review 1.  Uncommon headache syndromes in the pediatric population.

Authors:  Marco A Arruda; Regina C A P Albuquerque; Marcelo E Bigal
Journal:  Curr Pain Headache Rep       Date:  2011-08

Review 2.  Recurrent Painful Ophthalmoplegic Neuropathy and Oculomotor Nerve Schwannoma: A Pediatric Case Report with Long-Term MRI Follow-Up and Literature Review.

Authors:  Maria Giuseppina Petruzzelli; Mariella Margari; Flora Furente; Maria Carmela Costanza; Anna Rosi Legrottaglie; Franca Dicuonzo; Lucia Margari
Journal:  Pain Res Manag       Date:  2019-09-25       Impact factor: 3.037

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.